NDC 50242-078 – Susvimo
Ranibizumab 100 mg/mL · Injection, Solution · Intravitreal
Product NDC50242-078
Product details
- Brand name
- Susvimo
- Generic name
- Ranibizumab
- Labeler
- Genentech, Inc.
- Dosage form
- Injection, Solution
- Route
- Intravitreal
- Marketing category
- BLA · BLA761197
- Marketed since
- October 22, 2021
- Listing expires
- December 31, 2026
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Active ingredients
- Ranibizumab 100 mg/mL
Package NDC codes (2)
| Package NDC | Description | Since |
|---|---|---|
| 50242-078-12 | 1 VIAL in 1 CARTON (50242-078-12) / 1 mL in 1 VIAL | Oct 22, 2021 |
| 50242-078-55 | 1 VIAL in 1 CARTON (50242-078-55) / 1 mL in 1 VIAL | Oct 22, 2021 |
Recalls mentioning this NDC
- D-0025-2023 Nov 9, 2022 · Class III
Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the implants that renders it non-functioning.